Intarcia Therapeutics Stock
Intarcia Therapeutics is a biopharmaceutical company developing therapies for diseases that require long-term chronic treatment.
Sign up today and learn more about Intarcia Therapeutics Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Intarcia Therapeutics Stock
Intarcia Therapeutics, Inc. is a biopharmaceutical company that develops therapies for diseases that require long-term chronic treatment. It offers DUROS, a drug delivery platform that stabilizes and delivers therapeutic proteins and peptides. The company's products include OMEGA DUROS, an interferon delivery device for treating Hepatitis C and ITCA 650, a delivery device that provides type 2 diabetes patients with long-term steady state dosing of an incretin mimetic therapy. Additionally, it develops programs for treating obesity. The company was formerly known as BioMedicines, Inc. and changed its name to Intarcia Therapeutics, Inc. in September 2004. Intarcia Therapeutics was founded in 1997 and is based in Hayward, California with an additional office in Mountain View, California.
Investors
Pritzker Group Venture Capital
Scopely, Intarcia Therapeutics, project44, The Honest Company, Casper, Cameo, Heal, G2
Funding History
| May 2010 | $14.5M |
|---|---|
| September 2010 | $5.0M |
| January 2012 | $83.7M |
| August 2012 | $45.8M |
| November 2012 | $160M |
| November 2012 | $50.0M |
| April 2014 | $200M |
| April 2015 | $225M |
| May 2016 | $75.0M |
| September 2016 | $215M |
Management
CFO & Vice President, Finance and Operations
James M. Ahlers
Vice President, Global Regulatory Affairs and Quality
Sunita Zalani
Vice President, General Counsel, and Chief Legal Officer
Raymond Keane
Vice President, Human Resources
James P. Brady
Head of Customer Experience & Outcomes (CXO)
Jay Smith
Executive Director, DUROS® Manufacturing
Dick Ford
Chief Operating Officer
Michael Williams
Vice President, Chief Scientific Officer
Andrew Young
Head of Discovery and Translational Medicine
Paul Feldman
Vice President, General Counsel, Corporate Secretary
Barbara McClung
Press
EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
